Pandorum teams up with Bharat Biotech subsidiary
Pandorum Technologies has partnered with Bharat Biotech arm Nucelion Therapeutics to expand manufacturing of its exosome-based regenerative therapies across the Asia-Pacific region, strengthening regional supply, regulatory readiness and India’s biologics manufacturing capabilities
Hyderabad: Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, on Tuesday announced a strategic collaboration with Nucelion Therapeutics, a wholly-owned subsidiary of Bharat Biotech that specialises in contract research, development and manufacturing organisation (CRDMO), to expand manufacturing capabilities for Pandorum’s exosome-based therapeutic platform across Asia-Pacific (APAC) region.
By leveraging Nucelion Therapeutics’ manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward.
Furthermore, it reaffirms India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world, Pandorum Technologies in a statement on Tuesday said.
“Nucelion Therapeutics brings strong expertise in advanced biologics manufacturing and a high-quality operational environment that aligns well with our long-term vision of delivering programmable exosome therapies to patients worldwide,” says Dr Tuhin Bhowmick, PhD, Co-Founder and CEO, Pandorum Technologies.
